DUPUYTREN LITERATURE: REGULATION, FEEDBACK, INHIBITION

These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.

Medline Title Search (Dupuytren + (Regulat* or Feedback or Inhibit*))

Selected Publications

Intrinsic

• Alman BA, Greel DA, Ruby LK, Goldberg MJ, Wolfe HJ. (1996). “Regulation of Proliferation and Platelet-Derived Growth Factor Expression in Palmar Fibromatosis (Dupuytren Contracture) by Mechanical Strain.” J Orthop Res 14 (5): 722–28. (PDF)
• Alman Benjamin A, Greel Debra A, Ruby Leonard K, Goldberg Michael J, Wolfe Hubert J. (1996). “Regulation of Proliferation and Platelet-Derived Growth Factor Expression in Palmar Fibromatosis (Dupuytren Contracture) by Mechanical Strain.” Journal of Orthopaedic Research 14 (5): 722–28. http://www.ncbi.nlm.nih.gov/pubmed/8893764. (PDF)
• Hindman HB, Marty-Roix R, Tang JB, Jupiter JB, Simmons BP, Spector M. (2003). “ Regulation of Expression of Alpha-Smooth Muscle Actin in Cells of Dupuytren’s Contracture .” The Journal of Bone and Joint Surgery 85 (3): 448–55. (PDF)
• Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS. (2003). “Elevated Levels of Beta-Catenin and Fibronectin in Three-Dimensional Collagen Cultures of Dupuytren’s Disease Cells Are Regulated by Tension in Vitro.” BMC Musculoskelet Disord 4: 16. (PDF)
• Krause C, Kloen P. (2012). “Concurrent Inhibition of TGF-Beta and Mitogen Driven Signaling Cascades in Dupuytren’s Disease – Non-Surgical Treatment Strategies from a Signaling Point of View.” Med Hypotheses 78 (3): 385–88. (PDF)
• Matsui Yuichiro, Kon Shigeyuki, Funakoshi Tadanao, Miyashita Tomoe, Matsuda Tadashi, Iwasaki Norimasa. (2015). “Av Integrin Is a Crucial Regulator in the Development of Dupuytren Contracture.” The Journal of Hand Surgery 40 (9). Elsevier Inc: e46–47. http://linkinghub.elsevier.com/retrieve/pii/S0363502315007935. (PDF)
• Raykha C, Crawford J, Gan BS, Fu P, Bach LA, O’Gorman DB. (2013). “IGF-II and IGFBP-6 Regulate Cellular Contractility and Proliferation in Dupuytren’s Disease.” Biochim Biophys Acta 1832 (10): 1511–19. (PDF)
• Ulrich D, Hrynyschyn K, Pallua N. (2003). “Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Sera and Tissue of Patients with Dupuytren’s Disease.” Plast Reconstr Surg 112 (5): 1279–86. (PDF)
• Ulrich D, Ulrich F, Piatkowski A, Pallua N. (2009). “ Expression of Matrix Metalloproteinases and Their Inhibitors in Cords and Nodules of Patients with Dupuytren’s Disease .” Arch Orthop Trauma Surg 129 (11): 149–1453. http://www.ncbi.nlm.nih.gov/pubmed/18758795. (PDF)
• Verhoekx Jennifer SN, Mudera Vivek, Walbeehm Erik T, Hovius Steven ER. (2013). “Adipose-Derived Stem Cells Inhibit the Contractile Myofibroblast in Dupuytren’s Disease.” Plastic and Reconstructive Surgery 132 (5): 1139–48. http://www.ncbi.nlm.nih.gov/pubmed/23924646. (PDF)
• Verjee Liaquat Suleman, Midwood Kim, Davidson Dominique, Eastwood Mark, Nanchahal Jagdeep. (2010). “Post-Transcriptional Regulation of Alpha-Smooth Muscle Actin Determines the Contractile Phenotype of Dupuytren’s Nodular Cells.” J. Cell. Physiol. 224 (3): 681–90. http://www.ncbi.nlm.nih.gov/pubmed/20432463. (PDF)

Pharmacologic

• Chan Sze Wai, Vorobiof Daniel Alberto. (2015). “Dupuytren’s Contractures Associated with the BRAF Inhibitor Vemurafenib: A Case Report.” Journal of Medical Case Reports 9 (1). Journal of Medical Case Reports: 158. http://www.jmedicalcasereports.com/content/9/1/158. (PDF)
• Florence E, Schrooten W, Verdonck K, Dreezen C, Colebunders R. (2002). Rheumatological complications associated with the use of indinavir and other protease inhibitors. 2002/01/10, 61 Annals of the rheumatic diseases 82–84. (PDF)
• Hutchinson JW, Tierney GM, Parsons SL, Davis TR. (1998). “Dupuytren’s Disease and Frozen Shoulder Induced by Treatment with a Matrix Metalloproteinase Inhibitor.” J Bone Joint Surg Br 80 (5): 907–8. (PDF)
• Iqbal Syed Amir, Hayton Michael John, Watson James Stewart, Szczypa Piotr, Bayat Ardeshir. (2014). “First Identification of Resident and Circulating Fibrocytes in Dupuytren’s Disease Shown to Be Inhibited by Serum Amyloid P and Xiapex.” PloS One 9 (6): e99967. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4059720&tool=pmcentrez&rendertype=abstract. (PDF)
• Kang Young-Mi, Choi Yun-Rak, Yun Chae-Ok, Park Jin-Oh, Suk Kyung-Soo, Kim Hak-Sun, Park Moon-Soo, Lee Byung-Ho, Lee Hwan-Mo, Moon Seong-Hwan. (2013). “Down-Regulation of Collagen Synthesis and Matrix Metalloproteinase Expression in Myofibroblasts from Dupuytren Nodule Using Adenovirus-Mediated Relaxin Gene Therapy.” Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society 32 (4): 515–23. http://www.ncbi.nlm.nih.gov/pubmed/24293067. (PDF)
• Krzeski Piotr, Buckland-Wright Chris, Bálint Géza, Cline Gary A, Stoner Karen, Lyon Robert, Beary John, Aronstein William S, Spector Tim D. (2007). “Development of Musculoskeletal Toxicity without Clear Benefit after Administration of PG-116800, a Matrix Metalloproteinase Inhibitor, to Patients with Knee Osteoarthritis: A Randomized, 12-Month, Double-Blind, Placebo-Controlled Study.” Arthritis Research & Therapy 9 (5): R109. http://www.ncbi.nlm.nih.gov/pubmed/17958901. (PDF)
• Rayan GM, Parizi M, Tomasek JJ. (1996). “Pharmacologic Regulation of Dupuytren’s Fibroblast Contraction in Vitro.” J Hand Surg Am 21 (6): 1065–70. (PDF)
• Sibaud Vincent, Chevreau Christine. (2014). “Abrupt Development of Dupuytren’s Contractures with the BRAF Inhibitor Vemurafenib.” Joint, Bone, Spine : Revue Du Rhumatisme 33 (0): 9–11. http://www.ncbi.nlm.nih.gov/pubmed/24468667. (PDF)
• Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. (2008). “Matrix Metalloproteinase Inhibition Reduces Contraction by Dupuytren Fibroblasts.” J Hand Surg Am 33 (9): 1608–16. (PDF)
• Townley WA, Cambrey AD, Khaw PT, Grobbelaar AO. (2009). “The Role of an MMP Inhibitor in the Regulation of Mechanical Tension by Dupuytren’s Disease Fibroblasts.” The Journal of Hand Surgery, European Volume 34 (6): 783–87. http://www.ncbi.nlm.nih.gov/pubmed/10760640. (PDF)
• Verhoekx Jennifer SN, Verjee Liaquat S, Izadi D David, Chan James KK, Nicolaidou V Vicky, Davidson Dominique D, Midwood Kim S, Nanchahal Jagdeep J. (2013). “Isometric Contraction of Dupuytren’s Myofibroblasts Is Inhibited by Blocking Intercellular Junctions.” J Invest Dermatol , May. Nature Publishing Group. http://www.ncbi.nlm.nih.gov/pubmed/23652794. (PDF)
• Wong M, Mudera V. (2006). “Feedback Inhibition of High TGF-beta1 Concentrations on Myofibroblast Induction and Contraction by Dupuytren’s Fibroblasts.” J Hand Surg Br 31 (5): 473–83. (PDF)